Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13960303 | 0.85 | KCNA3 (0.66) | KCNA3 | |
| SCHEMBL24359592 | 0.81 | MEN1 (0.48) | MEN1KMT2ASLC6A3SLC6A4KCNA3 | |
| SCHEMBL24433074 | 0.81 | L3MBTL1 (0.51) | KCNA3 | |
| SCHEMBL13857882 | 0.79 | ALDH1A1 (0.55) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL6747206 | 0.78 | CXCR4 (0.65) | — | |
| SCHEMBL9020789 | 0.77 | SLC6A4 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| Lithium Ion SCHEMBL22470269 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2AKCNA3 | |
| SCHEMBL9906607 | 0.77 | KCNA3 (0.59) | MEN1KMT2AKCNA3HTR1ACACNA2D1 | |
| Hydrochloric Acid SCHEMBL10944441 | 0.76 | SIGMAR1 (0.61) | SLC6A3KCNA3SLC6A2 | |
| Hydrochloric Acid SCHEMBL9537230 | 0.76 | BCHE (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-4232437-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | Liangjiang Medicine Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | MEN1 1485/4885KMT2A 4380/4885SLC6A3 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.